A Risk-based Approach to Setting Sterile Filtration Bioburden Limits

Area of Science:

• Pharmaceutical Manufacturing
• Microbiology
• Regulatory Science

Background:

• Microbial control is essential for sterile drug product quality and safety.
• Pre-filtration bioburden monitoring is a key component of microbial control strategies.
• Regulatory guidelines (FDA, EMA) recommend specific pre-filtration bioburden limits (e.g., 10 CFU/100 mL).

Purpose of the Study:

• To introduce a risk-based method for establishing pre-filtration bioburden acceptance levels.
• To determine alternative test volumes for pre-filtration bioburden monitoring.
• To justify pre-filtration bioburden limits and volumes other than those recommended by current guidelines.

Main Methods:

• Statistical determination of the relationship between bioburden risk and sterile filtration parameters.
• Analysis of factors including filtration volume, filter surface area, and microbial retention capacity.
• Development of a risk-based approach for setting acceptance criteria.

Main Results:

• A statistically determined relationship between bioburden risk and sterile filtration parameters was established.
• The study demonstrates that alternative pre-filtration bioburden test volumes and acceptance limits can be justified.
• These alternative limits do not compromise the sterility assurance of the final drug product.

Conclusions:

• A risk-based method provides a scientifically sound basis for setting pre-filtration bioburden limits.
• Flexibility in setting bioburden limits and test volumes can be achieved without impacting product safety.
• This approach supports optimized microbial control strategies in sterile drug manufacturing.